FeesSafety
Pluang+

China includes Ascentage Pharma's lisaftoclax and renews olverembatinib coverage in 2026 National Reimbursement Drug List

Market News
16 Nov 2026, 01:30 WIB
GlobeNewsWire
View Source
Bullish
China includes Ascentage Pharma's lisaftoclax and renews olverembatinib coverage in 2026 National Reimbursement Drug List

Ascentage Pharma announced that its cancer drugs lisaftoclax and olverembatinib are now covered by China's 2026 National Reimbursement Drug List (NRDL), effective January 1, 2027. Lisaftoclax is newly included for treating chronic lymphocytic leukemia/small lymphocytic lymphoma, improving patient access to innovative treatments. Olverembatinib's coverage was successfully renewed for chronic myeloid leukemia patients, ensuring continued affordability and accessibility. This marks full NRDL coverage for all approved uses of both drugs, supporting domestic innovation and patient care in China.

Ascentage Pharma's cancer drugs and their reimbursement status provide context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 16, 2026 06:01 WIB: out of 150 priced US health-sector stocks, 71 rose and 77 fell. Notable movers include HNGE at USD 115.39 with a 1-day change of -4.63%, RXRX at USD 3.19 down 4.35%, and BNGO at USD 1.00 down 3.85%.

More News

DeGen Medical moves to dismiss Carlsmed's patent suit over spinal implant methods.

DeGen Medical moves to dismiss Carlsmed's patent suit over spinal implant methods.

DeGen Medical has filed a motion to dismiss key parts of a patent infringement lawsuit from Carlsmed, which claims DeGen's patient-specific spinal implants infringe on eight patents. DeGen argues that the contested patents cover abstract, computer-im...

Market News
Neutral
1 hour ago
SoFi projects 50% earnings growth in 2027 and no need for new capital raises.

SoFi projects 50% earnings growth in 2027 and no need for new capital raises.

SoFi announced it expects about 50% growth in earnings for 2027, signaling strong financial performance ahead. The company also stated it will not need to raise new capital, indicating confidence in its current funding and business model. This outloo...

Company Fundamentals
Bullish
2 hours ago
Jupiter (JUP) price correction halts near key support, signaling potential rebound if it surpasses $0.274.

Jupiter (JUP) price correction halts near key support, signaling potential rebound if it surpasses $0.274.

Jupiter (JUP) trades at $0.263, about 30% below its 12-month high and 92% above its low. The recent price correction stopped near the 200-day moving average at $0.242, a critical support level that buyers defended twice. For a trend reversal, JUP mus...

Technical Signals
Neutral
5 hours ago
Bitcoin drops below 200-week average amid extreme fear and ETF outflows, with no clear cause identified.

Bitcoin drops below 200-week average amid extreme fear and ETF outflows, with no clear cause identified.

Bitcoin recently fell 4.4% below its 200-week moving average, a rare event that coincides with a Fear and Greed Index reading of 10, signaling extreme market fear. Michael Saylor highlighted these metrics but did not link them directly to the price d...

Market News
Bearish
5 hours ago
All patients in Alpha Tau's glioblastoma trial alive with 100% tumor response and no serious side effects

All patients in Alpha Tau's glioblastoma trial alive with 100% tumor response and no serious side effects

Alpha Tau Medical announced interim results from its U.S. trial of Alpha DaRT therapy for recurrent glioblastoma, showing all eight treated patients are alive with a median follow-up of 6.9 months and no median survival reached. Among six patients as...

Market News
Bullish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App